KPV vs ARA-290
Both KPV and ARA-290 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Side-by-Side
| Attribute | KPV | ARA-290 |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy |
| Typical Dose | 200–500 mcg orally or topical (research only) | Trial range: 1–4 mg subcutaneous daily |
| Clinics Indexed | 26 | 9 |
| Categories | anti-inflammatory, gut-health, skin | anti-inflammatory, neuroprotection |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.